Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen

Journal of Medical Virology

Volumn 74, Issue 3, 2004, Pages 397-405

  Martin, P ^a   Parroche, P ^a   Chatel, L ^a   Barretto, C ^b   Beck, A ^b   Trepo C ^c   Bain, C ^a   Lone, Y C ^d   Inchauspe G ^a   Fournillier, Anne ^a  

^a BIOMÉRIEUX   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c HÔTEL DIEU   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

Cytotoxic T lymphocytes; HCV; IFN production; Immune response; PBMC; T epitopes

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; EPITOPE; GAMMA INTERFERON; HELICASE; HEPATITIS C VIRUS NS3 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 10; PEPTIDE; PEPTIDE LIBRARY; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE MAPPING; GENETIC SCREENING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SENSITIZATION; T LYMPHOCYTE; TARGET CELL; TRANSGENIC MOUSE; VIREMIA; VIRUS IMMUNITY;

AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; EPITOPES; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-10; MICE; MICE, TRANSGENIC; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; MUS MUSCULUS;

EID: 4644265609     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20189     Document Type: Article

References (40)

1. Arribillaga L, de Cerio AL, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borras-Cuesta F, Paranhos-Baccala G, Prieto J, Ruiz J, Lasarte JJ. 2002. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 21:202-210.
2. Barouch D, Friede T, Stevanovic S, Tussey L, Smith K, Rowland Jones S, Braud V, McMichael M, Rammensee HG. 1995. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 182:1847-1856.
3. Beck A, Goetsch L, Champion T, Bussat MC, Aubry JP, Klinguer-Hamour C, Haeuw JF, Bonnefoy JY, Corvaia N. 2001. Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals 29:293-298.
4. Booth JC, O'Grady J, Neuberger J. 2001. Clinical guidelines on the management of hepatitis C. Gut 49:11-21.
5. Brinster C, Muguet S, Lone YC, Boucreux D, Renard N, Fournillier A, Lemonnier F, Inchauspe G. 2001. Different hepatitis C virus nonstructural protein 3 (NS3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34:1206-1217.
6. Bronowicki JP, Vetter D, Uhl G, Hudziak H, Uhrlacher A, Vetter JM, Doffoel M. 1997. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients. J Infect Dis 176:518-522.
7. Buseyne F, Janvier G, Fleury B, Schmidt D, Riviere Y. 1994. Multi-specific and heterogeneous recognition of the gag protein by cytotoxic T lymphocytes (CTL) from HIV-infected patients: Factors other than the MHC control the epitopic specificities. Clin Exp Immunol 97:353-360.
8. Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, Fowler P, Houghton M, Chisari FV. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 95:521-530.
9. Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, McHutchison JG, Alter HJ, Chisari FV. 2001. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection. Hepatology 33:267-276.
10. Chen W, Anton LC, Bennink JR, Yewdell JW. 2000. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12:83-93.
11. Cohen J. 1999. The scientific challenge of hepatitis C virus. Science 285:26-30.
12. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, Pape GR. 1997. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71:6011-6019.
13. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, Hoffmann RM, Schirren CA, Santantonio T, Pape GR. 1999. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 117: 933-941.
14. Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N, Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia HM, Walker BD. 2001. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J Virol 75:1339-1347.
15. He XS, Rehermann B, Lopez-Labrador FX. 1999. Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 96: 5692-5697.
16. Himoudi N, Abraham J, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny M, Inchauspeacute; G. 2002. Comparative vaccine studies in HLA-A2.1 transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 76:12735-12746.
17. Ibe M, Sakaguchi T, Tanaka K, Saito S, Yokota S, Tanaka T, Shimotohno K, Chujoh Y, Shiratori Y, Omata M, Miwa K, Takiguchi M. 1998. Identification and characterization of a cytotoxic T cell epitope of hepatitis C virus presented by HLA-B*3501 in acute hepatitis. J Gen Virol 79:1735-1744.
18. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJ, Sette A. 1994. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 152:3904-3912.
19. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87:9524-9528.
20. Kurokohchi K, Akatsuka T, Pendleton CD, Takamizawa A, Nishioka M, Battegay M, Feinstone SM, Berzofsky JA. 1996. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 70:232-240.
21. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, Kim AY, Lucas M, Klenerman P, Walker BD. 2002. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76:6104-6113.
22. Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, Cerny A, Phillips R, Ferrari C, Pape GR, Klenerman P. 2000a. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30:2479-2487.
23. Lechner F, Wong DK, Dunbar PR, Chapman RT, Chung RT, Dohrenwend P, Robbins G, Philips R, Klenerman P, Walker BD. 2000b. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191:1499-1512.
24. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132:296-305.
25. Lone YC, Motta I, Mottez E, Guilloux Y, Lim A, Demay F, Levraud JP, Kourilsky P, Abastado JP. 1998. In vitro induction of specific cytotoxic T lymphocytes using recombinant single-chain MHC class I/peptide complexes. J Immunother 21:283-294.
26. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, More C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C. 1996. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98:706-714.
27. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. 1997. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185:2043-2051.
28. Prezzi C, Casciaro MA, Francavilla V, Schiafella E, Finocchi L, Chircu LV, Bruno G, Sette A, Abrigiani S, Barnaba V. 2001. Virus-specific CD8+ T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 31:894-906.
29. Racanelli V, Rehermann B. 2003. Hepatitis C virus infection: When silence is deception. Trends Immunol 24:456-464.
30. Rodda SJ. 2002. Peptide libraries for T cell epitope screening and characterization. J Immunol Methods 267:71-77.
31. Rosen HR, Miner C, Lewinsohn D, Sasaki AW, Conrad AJ, Bakke A, Bouwer A. 2002. Determination of Hepatitis C virus-specific effector CD4+ T cell by flow cytometry: Correlation with clinical disease stages. Hepatology 35:190-198.
32. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578-582.
33. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395-1406.
34. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K. 2000. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: Implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411-3421.
35. Urbani S, Uggeri J, Matsuura Y, Miyamura T, Penna A, Boni C, Ferrari C. 2001. Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology 33:1533-1543.
36. Vertuani S, Bazzaro M, Gualandi G, Micheletti F, Marastoni M, Fortini C, Canella A, Marino M, Tomatis R, Traniello S, Gavioli R. 2002. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 32:144-154.
37. Ward S, Lauer G, Isba R, Walker B, Klenerman P. 2002. Cellular immune responses against hepatitis C virus: The evidence base 2002. Clin Exp Immunol 128:195-203.
38. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B. 2002. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169:3447-3458.
39. Wentworth PA, Sette A, Celis E, Sidney J, Southwood S, Crimi C, Stitely S, Keogh E, Wong NC, Livingston B, Alazard D, Vitiello A, Grey HM, Chisari FV, Chesnut RW, Fikes J. 1996. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 8:651-659.
40. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. 2003. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37:577-589.